IFPMA Note for Guidance on sponsorship of events and meetings (2023 update)
Advancing medical knowledge and improving global public health remains a priority for IFPMA representing the research-based pharmaceutical industry.
Collaborations between healthcare professionals (HCPs) and the pharmaceutical industry are essential and ensure that patients have access to the medicines they need and that healthcare professionals have up-to-date comprehensive information about the diseases they treat and the medicines they prescribe.
IFPMA members remain committed to activities that provide scientific and educational content to healthcare professionals and advance their medical knowledge and expertise.
The purpose of this document is to provide more information in relation to relevant requirements of the IFPMA Code of Practice.
Related news and resources
Enhanced collaboration between anti-doping agency and big pharma bolsters support for clean sport among athletes
On 3 April 2024 in Athens, the International Federationof Pharmaceutical Manufacturers and Associations (IFPMA) and the World Anti-Doping Agency (WADA) signed a joint letter of intent.
Read moreOur Ethos in Action – Decision-Making Framework Toolkit
IFPMA has developed a Five-Phase Decision-Making Framework, grounded in the IFPMA Ethos or value system, to help companies make decisions that balance business objectives and ethical considerations to meet patient needs and the expectations of the medical community, regulators, and society.
Read more
IFPMA and industry leaders applaud 10 years of collective action on ethics and business integrity in APEC region
Washington, D.C. and Geneva, 26 September 2023: This week, IFPMA joins hundreds of stakeholders from across economies in the Asia-Pacific at the APEC Business Ethics for SMEs Forum to recognize and applaud progress made by the initiative in the past decade to advance business ethics in the medical device and biopharmaceutical sectors in the region....
Read more